141 related articles for article (PubMed ID: 29948962)
1. The Parker Model: Applying a Qualitative Three-Step Approach to Optimally Utilize Input from Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic Diseases.
Jørgensen TS; Skougaard M; Taylor PC; Asmussen HC; Lee A; Klokker L; Svejstrup L; Mountian I; Gudbergsen H; Kristensen LE
Patient; 2018 Oct; 11(5):515-526. PubMed ID: 29948962
[TBL] [Abstract][Full Text] [Related]
2. Using Patient Feedback to Optimize the Design of a Certolizumab Pegol Electromechanical Self-Injection Device: Insights from Human Factors Studies.
Domańska B; Stumpp O; Poon S; Oray S; Mountian I; Pichon C
Adv Ther; 2018 Jan; 35(1):100-115. PubMed ID: 29222625
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, open-label study to evaluate the safe and effective use of a new electromechanical auto-injection device for self-injection of certolizumab pegol.
Tatla D; Mountian I; Szegvari B; VanLunen B; Schiff M
Expert Opin Drug Deliv; 2020 Jun; 17(6):855-862. PubMed ID: 32239971
[TBL] [Abstract][Full Text] [Related]
4. A pilot study examining patient preference and satisfaction for ava®, a reusable electronic injection device to administer certolizumab pegol.
Pouls BPH; Kristensen LE; Petersson M; van den Bemt BJF; Ballerini L; Bruggraber R; Karlen H; Mountian I; van Bracht E; Wiegratz S; Jørgensen TS
Expert Opin Drug Deliv; 2020 May; 17(5):705-711. PubMed ID: 32154740
[No Abstract] [Full Text] [Related]
5. Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis.
Domańska B; VanLunen B; Peterson L; Mountian I; Schiff M
Expert Opin Drug Deliv; 2017 Jan; 14(1):15-22. PubMed ID: 27801596
[TBL] [Abstract][Full Text] [Related]
6. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
[TBL] [Abstract][Full Text] [Related]
7. Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study.
Lopalco G; Emmi G; Gentileschi S; Guerriero S; Vitale A; Silvestri E; Becatti M; Cavallo I; Fabiani C; Frediani B; Iannone F; Cantarini L
Mod Rheumatol; 2017 Nov; 27(6):1031-1035. PubMed ID: 28712320
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
[TBL] [Abstract][Full Text] [Related]
9. Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis.
Takeuchi T; Yamamoto K; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Kobayashi M; Shoji T; Togo O; Miyasaka N; Koike T
Mod Rheumatol; 2016 Jul; 26(4):473-80. PubMed ID: 26472043
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
12. Rheumatic diseases should be actively treated in pregnancy, new guidelines say.
Wise J
BMJ; 2016 Jan; 532():i312. PubMed ID: 26787749
[No Abstract] [Full Text] [Related]
13. Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.
Deeks ED
BioDrugs; 2016 Dec; 30(6):607-617. PubMed ID: 27704400
[TBL] [Abstract][Full Text] [Related]
14. Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
Sieper J; Kivitz A; van Tubergen A; Deodhar A; Coteur G; Woltering F; Landewé R
Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1475-80. PubMed ID: 25832312
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
Atsumi T; Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Togo O; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2017 Aug; 76(8):1348-1356. PubMed ID: 28153828
[TBL] [Abstract][Full Text] [Related]
16. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study.
Clowse ME; Förger F; Hwang C; Thorp J; Dolhain RJ; van Tubergen A; Shaughnessy L; Simpson J; Teil M; Toublanc N; Wang M; Hale TW
Ann Rheum Dis; 2017 Nov; 76(11):1890-1896. PubMed ID: 28814432
[TBL] [Abstract][Full Text] [Related]
17. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
[TBL] [Abstract][Full Text] [Related]
18. Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland.
Soini E; Asseburg C; Taiha M; Puolakka K; Purcaru O; Luosujärvi R
Adv Ther; 2017 Oct; 34(10):2316-2332. PubMed ID: 28975568
[TBL] [Abstract][Full Text] [Related]
19. Infections and Biological Therapy in Patients with Rheumatic Diseases.
Atzeni F; Batticciotto A; Masala IF; Talotta R; Benucci M; Sarzi-Puttini P
Isr Med Assoc J; 2016; 18(3-4):164-7. PubMed ID: 27228636
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
